Research programme: protein-degradation therapies - Kymera Therapeutics
Latest Information Update: 28 Feb 2025
At a glance
- Originator Kymera Therapeutics
- Class Anti-inflammatories; Antineoplastics; Antipsoriatics; Small molecules
- Mechanism of Action Proteolysis; STAT3 transcription factor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders; Fibrosis; Lymphoma; Solid tumours
Most Recent Events
- 28 Feb 2025 No recent reports of development identified for preclinical development in Lymphoma in USA (PO)
- 28 Feb 2025 No recent reports of development identified for preclinical development in Solid-tumours in USA (PO)
- 28 Feb 2025 No recent reports of development identified for research development in Autoimmune-disorders in USA (PO)